File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Elevation of methylated DNA in KILLIN/PTEN in the plasma of patients with thyroid and/or breast cancer

TitleElevation of methylated DNA in KILLIN/PTEN in the plasma of patients with thyroid and/or breast cancer
Authors
KeywordsThyroid cancer
PTEN
KILLIN
Hypermethylation
Breast cancer
Issue Date2014
Citation
OncoTargets and Therapy, 2014, v. 7, p. 2085-2092 How to Cite?
Abstract© 2014 Ng et al. Around 80% of mutations in the PTEN gene have been reported to be associated with diseases such as Cowden syndrome, which is an autosomal dominant disorder associated with an increased risk of developing breast, thyroid, and endometrial neoplasms. Recent studies have also demonstrated that KILLIN, which is located proximally to PTEN, shares the same transcription start site, and is assumed to be regulated by the same promoter, but is transcribed in the opposite direction. In this regard, we postulate that there may be a connection between KILLIN/PTEN genes and breast and thyroid cancers. Using real-time quantitative polymerase chain reaction (qPCR), we found that expression of KILLIN, but not PTEN, was significantly decreased in 23 Chinese women with a personal history of breast and thyroid cancer or a personal history of breast cancer and a family history of thyroid cancer, or vice versa, and at least two persons in the family with thyroid cancer or at a young age ,40 years, when compared with healthy controls (P<0.0001). No PTEN mutations were found in these 23 patients. We then developed a simple methylation-sensitive restriction enzyme digestion followed by real-time quantitative assay to quantify plasma methylated KILLIN/PTEN DNA in these patients. Plasma levels of methylated KILLIN/PTEN DNA were significantly increased in these patients when compared with healthy controls (P<0.05). This study shows that plasma methylated KILLIN/PTEN DNA was significantly elevated, suggesting hypermethylation of the KILLIN/PTEN promoter in breast and thyroid cancer patients.
Persistent Identifierhttp://hdl.handle.net/10722/207546
ISSN
2015 Impact Factor: 2.272
2015 SCImago Journal Rankings: 1.133

 

DC FieldValueLanguage
dc.contributor.authorNg, Kaion-
dc.contributor.authorShin, Vivianyvonne-
dc.contributor.authorLeung, Candy P H-
dc.contributor.authorChan, Vivian W.-
dc.contributor.authorLaw, Fian Bic Fai-
dc.contributor.authorSiu, Man T.-
dc.contributor.authorLang, Brian-
dc.contributor.authorMa, Edmond Siu Kwan-
dc.contributor.authorKwong, Ava-
dc.date.accessioned2014-12-31T01:01:51Z-
dc.date.available2014-12-31T01:01:51Z-
dc.date.issued2014-
dc.identifier.citationOncoTargets and Therapy, 2014, v. 7, p. 2085-2092-
dc.identifier.issn1178-6930-
dc.identifier.urihttp://hdl.handle.net/10722/207546-
dc.description.abstract© 2014 Ng et al. Around 80% of mutations in the PTEN gene have been reported to be associated with diseases such as Cowden syndrome, which is an autosomal dominant disorder associated with an increased risk of developing breast, thyroid, and endometrial neoplasms. Recent studies have also demonstrated that KILLIN, which is located proximally to PTEN, shares the same transcription start site, and is assumed to be regulated by the same promoter, but is transcribed in the opposite direction. In this regard, we postulate that there may be a connection between KILLIN/PTEN genes and breast and thyroid cancers. Using real-time quantitative polymerase chain reaction (qPCR), we found that expression of KILLIN, but not PTEN, was significantly decreased in 23 Chinese women with a personal history of breast and thyroid cancer or a personal history of breast cancer and a family history of thyroid cancer, or vice versa, and at least two persons in the family with thyroid cancer or at a young age ,40 years, when compared with healthy controls (P<0.0001). No PTEN mutations were found in these 23 patients. We then developed a simple methylation-sensitive restriction enzyme digestion followed by real-time quantitative assay to quantify plasma methylated KILLIN/PTEN DNA in these patients. Plasma levels of methylated KILLIN/PTEN DNA were significantly increased in these patients when compared with healthy controls (P<0.05). This study shows that plasma methylated KILLIN/PTEN DNA was significantly elevated, suggesting hypermethylation of the KILLIN/PTEN promoter in breast and thyroid cancer patients.-
dc.languageeng-
dc.relation.ispartofOncoTargets and Therapy-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectThyroid cancer-
dc.subjectPTEN-
dc.subjectKILLIN-
dc.subjectHypermethylation-
dc.subjectBreast cancer-
dc.titleElevation of methylated DNA in KILLIN/PTEN in the plasma of patients with thyroid and/or breast cancer-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.2147/OTT.S53597-
dc.identifier.scopuseid_2-s2.0-84910651485-
dc.identifier.hkuros241691-
dc.identifier.volume7-
dc.identifier.spage2085-
dc.identifier.epage2092-
dc.identifier.eissn1178-6930-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats